Key Takeaways
- • Transaction volume collapsed 67% in H1 2026 versus H1 2025, but aggregate deal value increased nearly 10%, signaling PE sponsors are concentrating capital on higher-conviction megadeals rather than deploying broadly across the market.
- • Fundraising dollars rose 9% in H1 2026 despite fewer funds raised, as established managers with strong distributions-to-paid-in-capital (DPI) captured an outsized share of LP commitments, while underperforming sponsors faced extended timelines and reduced targets.
- • Exit bottlenecks persist with narrow IPO windows and selective strategic buyer appetite, forcing sponsors to rely increasingly on continuation vehicles and GP-led secondaries as primary liquidity mechanisms—functional solutions facing growing LP skepticism around conflicts of interest.
- • Healthcare remains PE's most resilient deployment sector with take-privates and platform roll-ups proceeding at pace, while Technology faces a complex environment as AI disrupts legacy software holdings and complicates exit timing despite creating new value creation opportunities.
- • The middle market experienced acute hesitation driven by valuation gaps that neither buyers nor sellers are willing to bridge, reflecting a structural recalibration in LP allocation priorities driven by years of compounded unreturned capital.
Summary
Private equity's first half of 2026 presents a tale of two markets: dramatic transaction scarcity paired with concentrated deal sizing and stable capital deployment. The 67% decline in overall PE transactions masks a critical market dynamic—those deals that closed skewed substantially larger, with aggregate deal value rising nearly 10% year-over-year. This divergence reflects a deliberate strategic pivot by sponsors away from broad deployment toward higher-conviction opportunities, a meaningful shift in dealmaking mentality.
The fundraising environment reinforces this concentration thesis. Despite a slight decline in the number of funds raised, aggregate capital commitments increased 9% in the first half of 2026 compared to the same period in 2025. The driver is structural and selective: established managers demonstrating strong distributions-to-paid-in-capital metrics raised capital quickly, while peers without proven track records faced extended fundraising timelines, reduced capital targets, and increasingly scrutinizing LP investment committees. This bifurcation reflects a fundamental recalibration of LP behavior in an environment where unreturned capital has accumulated over multiple years, tightening investment discipline.
The exit environment remains the industry's primary constraint. IPO windows remain narrow, strategic buyer appetite is selective rather than opportunistic, and sponsor-to-sponsor transactions continue to face valuation scrutiny. In response, continuation vehicles and GP-led secondaries have become the market's primary liquidity mechanisms. While these structures provide functional exits, they increasingly face LP skepticism regarding conflicts of interest—a structural tension that will likely persist absent broader market recovery in traditional exit channels.
Sector divergence is pronounced. Healthcare has emerged as private equity's most resilient deployment area, with take-private transactions and platform roll-ups proceeding at scale despite broader market hesitation. Technology, historically PE's highest-returning sector, faces a more complex calculus as artificial intelligence disrupts the fundamental economics of legacy software holdings, simultaneously complicating exit timing while potentially unlocking new value creation levers for forward-looking sponsors. The middle market, meanwhile, experienced acute deal hesitation driven by persistent valuation gaps between buyers and sellers that neither party is willing to breach—a dynamic that reflects broader uncertainty rather than fundamental sector challenges.
The fundraising environment reinforces this concentration thesis. Despite a slight decline in the number of funds raised, aggregate capital commitments increased 9% in the first half of 2026 compared to the same period in 2025. The driver is structural and selective: established managers demonstrating strong distributions-to-paid-in-capital metrics raised capital quickly, while peers without proven track records faced extended fundraising timelines, reduced capital targets, and increasingly scrutinizing LP investment committees. This bifurcation reflects a fundamental recalibration of LP behavior in an environment where unreturned capital has accumulated over multiple years, tightening investment discipline.
The exit environment remains the industry's primary constraint. IPO windows remain narrow, strategic buyer appetite is selective rather than opportunistic, and sponsor-to-sponsor transactions continue to face valuation scrutiny. In response, continuation vehicles and GP-led secondaries have become the market's primary liquidity mechanisms. While these structures provide functional exits, they increasingly face LP skepticism regarding conflicts of interest—a structural tension that will likely persist absent broader market recovery in traditional exit channels.
Sector divergence is pronounced. Healthcare has emerged as private equity's most resilient deployment area, with take-private transactions and platform roll-ups proceeding at scale despite broader market hesitation. Technology, historically PE's highest-returning sector, faces a more complex calculus as artificial intelligence disrupts the fundamental economics of legacy software holdings, simultaneously complicating exit timing while potentially unlocking new value creation levers for forward-looking sponsors. The middle market, meanwhile, experienced acute deal hesitation driven by persistent valuation gaps between buyers and sellers that neither party is willing to breach—a dynamic that reflects broader uncertainty rather than fundamental sector challenges.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.